MENU

Windfall: Sirtex Medical Limited receives second takeover bid at $33.60

Sirtex Medical Limited (ASX:SRX) exited a trading halt on Friday, after announcing that it had received a second takeover bid from China-based CDH Investments at $33.60/share.

The new, conditional bid has led to Sirtex adjourning its shareholder meeting so that it can consider the proposal. Director’s fiduciary duties mandate that they must consider all options for maximising the value of shareholders, so the CDH Investments bid could lead to a delay in the Sirtex takeover process.

As we have reported previously, Sirtex is currently under a binding takeover offer from Varian Medical Systems, valuing Sirtex at $28 per share. The Sirtex Board has unanimously voted in favour, and the Foreign Investment Review Board (FIRB) announced that it had no objection to the takeover. The final step was to have shareholders vote on the arrangement.

However, the CDH bid has now thrown somewhat of a spanner in the works, by delaying the proposed shareholder meeting. Indeed, it’s possible the bid may have been lobbed deliberately late, in an attempt to either frustrate Varian’s attempt or try to achieve a stronger bargaining position for CDH.

There is a chance that the CDH bid goes through, and there could be an ‘arbitrage’ opportunity available (buy shares at $29 today and sell them at $33.60 if the CDH bid eventuates). However, it is far from a certainty that a higher bid will emerge – either from CDH or from Varian. CDH may just wish to get a look at Sirtex’s books to better evaluate what it is worth.

In my opinion, shareholders should watch from the sidelines for now.

OUR #1 dividend pick to grow your wealth over the new financial year is revealed for FREE here!

Financial year 2018 is here and The Motley Fool’s dividend detective Andrew Page has revealed his must buy dividend share to grow your wealth in 2018.

You might not know this market leader's name, but it's rapidly expanding into a highly profitable niche market here in Australia. Even better, the shares boast a strong, fully franked dividend that should balloon in the years to come. In other words, we're looking at the holy grail of incredible long-term growth potential AND income you can watch accruing in your account in real time!

Simply click here to grab your FREE copy of this up-to-the-minute research report on our #1 dividend share recommendation now.

Motley Fool contributor Sean O'Neill owns shares of Sirtex Medical Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.